Cassava Sciences: Data For Mild Alzheimer's Disease Patients Provides Good Risk/Reward Profile

Jan. 26, 2023 2:01 PM ETCassava Sciences, Inc. (SAVA)151 Comments
Jacob Braun profile picture
Jacob Braun


  • Cassava Sciences released data for over 200 patients in an open-label trial at 12 months.
  • The mild AD subgroup performed unprecedentedly.
  • Cassava Sciences has had two major institutional purchases recently.
Senior woman with headache sitting in the bed at home

FG Trade/E+ via Getty Images


I continue to maintain a strong buy rating on Cassava Sciences (NASDAQ:SAVA). I believe that Cassava Sciences presents a favorable risk-to-reward ratio considering the massive potential gains to be made upon the successful launch of an Alzheimer's Drug (AD).

This article was written by

Jacob Braun profile picture
To follow all work, follow my Twitter @realjacobbraun

Disclosure: I/we have a beneficial long position in the shares of SAVA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (151)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.